Esmolol (Brevibloc)
Ultra-short-acting beta-1-selective (cardioselective) adrenergic antagonist
Esmolol (Brevibloc)
Forms and strengths
Form: TabletStrength: 10 mg/mL (100 mg/10 mL vial; 2500 mg/250 mL premixed bag)
References
Indication
- Rapid control of ventricular rate in atrial fibrillation or atrial flutter in acute situations when a short-acting agent is preferred.
- Management of postintubation tachycardia and hypertension, and other acute perioperative tachycardia where rapid, easily titratable, easily reversible beta-blockade is needed.
- Used as a second-line acute agent for regular narrow-complex supraventricular tachycardia (AVNRT/AVRT) when adenosine has failed, is contraindicated, or symptoms recur after transient termination, particularly when an IV beta-blocker is preferred over an IV calcium channel blocker (e.g., borderline blood pressure, need for a rapidly reversible agent).
- For short-term use only (up to 24 hours); not indicated for chronic use.
Pregnancy
- Limited human data. Beta-blockers as a class can cause fetal bradycardia, hypotension, hypoglycemia, and growth restriction with prolonged use — reserve for situations where the potential maternal benefit clearly outweighs the potential fetal risk, and rely on esmolol's ultra-short half-life to limit the duration of fetal exposure once the acute indication has resolved.
Breastfeeding
- No dedicated human lactation data. Given the very short elimination half-life, systemic infant exposure after a maternal infusion is expected to be low, but use with caution and monitor the infant if breastfeeding during or shortly after an esmolol infusion.
Geriatrics
- No specific contraindication, but older adults may be more sensitive to the hypotensive and bradycardic effects of beta-blockade — titrate cautiously and monitor blood pressure/heart rate closely throughout the infusion.
Pediatrics
- Safety and effectiveness in pediatric patients have not been established in the Canadian product monograph; use only under specialist direction if needed.
Dosage & Administration
- Atrial fibrillation/flutter rate control, or second-line acute SVT rate control: loading dose infusion of 0.5 mg/kg/min for 1 minute, followed by a maintenance infusion of 0.05 mg/kg/min for 4 minutes.
- If the response is inadequate, repeat the loading dose (0.5 mg/kg/min for 1 minute) and increase the maintenance infusion to 0.1 mg/kg/min; continue this titration in increments of 0.05 mg/kg/min up to a maximum maintenance infusion of 0.2 mg/kg/min.
- As the desired heart rate or a safety endpoint (e.g., falling blood pressure) is approached, omit the loading dose and reduce the maintenance-infusion increment to 0.025 mg/kg/min or lower, or extend the interval between titration steps from 5 to 10 minutes.
- Postintubation tachycardia/hypertension: 1.5 mg/kg (maximum 100 mg) as a bolus injection over 30 seconds, given 1-2 minutes before intubation.
- Administer via infusion pump for precise control; the initial loading dose may be given by hand-held syringe from the premixed bag while the maintenance infusion is prepared. Requires continuous ECG and blood pressure monitoring throughout.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Manifests as hypotension, bradycardia, and reduced level of consciousness. Because of the very short half-life, most overdose effects resolve within minutes of stopping the infusion; supportive care (IV fluids, atropine for symptomatic bradycardia, vasopressors for persistent hypotension) is the mainstay while the infusion is held — contact Poison Control or seek emergency care immediately.
Common side effects
- Hypotension.
- Injection-site reactions (burning, inflammation).
- Dizziness, somnolence.
- Nausea.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Symptomatic hypotension, severe bradycardia, and AV block.
- Bronchospasm in patients with reactive airway disease — beta-1 selectivity is relative and can be lost at higher infusion rates.
- Skin necrosis or sloughing has been reported with extravasation — use a secure, large-bore line and monitor the infusion site closely.
Use with caution
- Use with caution in reactive airway disease/bronchospasm, compensated heart failure, and diabetes (beta-blockade can mask the tachycardia and tremor of hypoglycemia).
- Use with caution in renal impairment — the acid metabolite is renally eliminated and may accumulate, though clearance of the parent drug itself is not primarily renal.
Contraindications
- Patients requiring inotropic or vasopressor support to maintain blood pressure and cardiac output.
- Hypotension, sinus bradycardia, sick sinus syndrome, second- or third-degree AV block without a functioning pacemaker, pulmonary hypertension, right ventricular failure secondary to pulmonary hypertension.
- Concurrent use, or use within 24 hours, of an IV nondihydropyridine calcium channel blocker (verapamil, diltiazem) — fatal cardiac arrests have occurred with esmolol given together with IV verapamil.
- Decompensated heart failure.
Drug interactions
- IV verapamil or diltiazem: contraindicated within 24 hours of esmolol in either direction — additive, potentially fatal bradycardia and cardiodepression.
- Digoxin: esmolol can modestly increase digoxin levels — monitor.
- Other agents that slow AV conduction (amiodarone, other beta-blockers): additive bradycardia/AV block.
- Succinylcholine: esmolol may prolong its neuromuscular blocking effect.
Food interactions
- None significant — esmolol is given only by IV infusion.
Time of administration
- Continuous IV infusion titrated by trained personnel with continuous ECG and blood pressure monitoring; not applicable to a fixed daily administration schedule.
Storage
- Store per institutional pharmacy protocol; use premixed bags and any further-diluted preparations within the stated in-use stability window.
Patient take-away
- This medication is given only in a monitored hospital or emergency setting by IV infusion — there is no take-home version.
- Report any burning, swelling, or pain at the IV site immediately.
- Tell the care team about any history of asthma or severe lung disease before this medication is started.